PT3359528T - Agonistas de ppar, compostos, composições farmacêuticas e métodos de utilização dos mesmos - Google Patents
Agonistas de ppar, compostos, composições farmacêuticas e métodos de utilização dos mesmosInfo
- Publication number
- PT3359528T PT3359528T PT167856111T PT16785611T PT3359528T PT 3359528 T PT3359528 T PT 3359528T PT 167856111 T PT167856111 T PT 167856111T PT 16785611 T PT16785611 T PT 16785611T PT 3359528 T PT3359528 T PT 3359528T
- Authority
- PT
- Portugal
- Prior art keywords
- compounds
- methods
- pharmaceutical compositions
- ppar agonists
- ppar
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
- C07D233/60—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with hydrocarbon radicals, substituted by oxygen or sulfur atoms, attached to ring nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562238629P | 2015-10-07 | 2015-10-07 | |
US201562243263P | 2015-10-19 | 2015-10-19 | |
US201662352348P | 2016-06-20 | 2016-06-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
PT3359528T true PT3359528T (pt) | 2022-04-07 |
Family
ID=57200096
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PT167856111T PT3359528T (pt) | 2015-10-07 | 2016-10-05 | Agonistas de ppar, compostos, composições farmacêuticas e métodos de utilização dos mesmos |
Country Status (26)
Country | Link |
---|---|
US (5) | US10399958B2 (pt) |
EP (3) | EP3770146A1 (pt) |
JP (2) | JP6657413B2 (pt) |
KR (2) | KR20210126150A (pt) |
CN (3) | CN113024467A (pt) |
AU (3) | AU2016333963C1 (pt) |
BR (1) | BR112018006866B1 (pt) |
CA (1) | CA3000431A1 (pt) |
CO (1) | CO2018004473A2 (pt) |
DK (1) | DK3359528T3 (pt) |
EA (1) | EA037371B1 (pt) |
ES (2) | ES2906379T3 (pt) |
HK (1) | HK1257907A1 (pt) |
HU (1) | HUE058154T2 (pt) |
IL (3) | IL258225B (pt) |
JO (3) | JO3738B1 (pt) |
MA (2) | MA52648A (pt) |
MX (2) | MX2020011099A (pt) |
PH (1) | PH12018500762A1 (pt) |
PL (1) | PL3359528T3 (pt) |
PT (1) | PT3359528T (pt) |
SG (1) | SG10201906400SA (pt) |
TW (3) | TWI730408B (pt) |
UA (1) | UA122237C2 (pt) |
WO (1) | WO2017062468A1 (pt) |
ZA (4) | ZA201802029B (pt) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK3359528T3 (en) | 2015-10-07 | 2022-03-07 | Mitobridge Inc | Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof |
KR102430906B1 (ko) | 2016-04-13 | 2022-08-10 | 미토브리지, 인크. | Ppar 효능제, 화합물, 제약 조성물, 및 그의 사용 방법 |
US20210283116A1 (en) * | 2016-10-05 | 2021-09-16 | Mitobridge, Inc. | Methods of treating acute kidney injury |
PL3523283T3 (pl) * | 2016-10-05 | 2021-12-13 | Mitobridge, Inc. | Postacie krystaliczne i postacie soli związków stanowiących agonistów ppar |
US20220331267A1 (en) * | 2019-09-05 | 2022-10-20 | Rush University Medical Center | Methods and compositions for treatment of demyelinating disorders |
US11634387B2 (en) | 2019-09-26 | 2023-04-25 | Abionyx Pharma Sa | Compounds useful for treating liver diseases |
WO2022189856A1 (en) | 2021-03-08 | 2022-09-15 | Abionyx Pharma Sa | Compounds useful for treating liver diseases |
CA3221429A1 (en) | 2021-06-02 | 2022-12-08 | Astellas Pharma Inc. | Methods of use of ppar agonist compounds and pharmaceutical compositions thereof |
WO2023147309A1 (en) | 2022-01-25 | 2023-08-03 | Reneo Pharmaceuticals, Inc. | Use of ppar-delta agonists in the treatment of disease |
EP4230196A1 (en) | 2022-02-21 | 2023-08-23 | Som Innovation Biotech, S.A. | Compounds for use in the treatment of dystrophinopathies |
Family Cites Families (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4228281A (en) | 1977-09-23 | 1980-10-14 | Ciba-Geigy Corporation | Dicarboxylic acids containing triazine rings |
DE4123341A1 (de) * | 1991-07-15 | 1993-01-21 | Thomae Gmbh Dr K | Phenylalkylderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung |
GB9511694D0 (en) | 1995-06-09 | 1995-08-02 | Fujisawa Pharmaceutical Co | Benzamide derivatives |
AU773273B2 (en) | 1999-02-26 | 2004-05-20 | Bristol-Myers Squibb Company | Novel sulfonamide compounds and uses thereof |
GB9919413D0 (en) | 1999-08-18 | 1999-10-20 | Zeneca Ltd | Chemical compounds |
SK1732003A3 (en) | 2000-08-17 | 2004-08-03 | Pfizer | Substituted imidazoles as TAFIa inhibitors |
ES2342596T3 (es) * | 2002-08-29 | 2010-07-09 | MERCK SHARP & DOHME CORP. | Indoles con actividad anti-diabetica. |
WO2004031118A1 (ja) | 2002-10-03 | 2004-04-15 | Ono Pharmaceutical Co., Ltd. | Lpa受容体拮抗剤 |
WO2004060367A1 (en) | 2002-12-30 | 2004-07-22 | Fujisawa Pharmaceutical Co., Ltd. | Imidazole and triazole derivatives useful as selective cox-1 inhibitors |
MXPA06003357A (es) | 2003-09-26 | 2006-06-08 | Japan Tobacco Inc | Metodo para inhibir la produccion de lipoproteina remanente. |
JP2008512364A (ja) | 2004-09-06 | 2008-04-24 | エフ.ホフマン−ラ ロシュ アーゲー | 4−アミノメチルベンズアミジン誘導体及び第VIIa因子阻害剤としてのその使用 |
WO2007028424A1 (en) | 2005-02-15 | 2007-03-15 | F. Hoffmann-La Roche Ag | Amide derivatives as ppar activators |
AU2006287521A1 (en) | 2005-09-07 | 2007-03-15 | Plexxikon, Inc. | PPARactive compounds |
CN101374835B (zh) | 2006-01-30 | 2012-04-25 | 转化技术制药公司 | 作为PTPase抑制剂的取代的咪唑衍生物、组合物和使用方法 |
WO2007110237A2 (en) | 2006-03-28 | 2007-10-04 | Novartis Ag | Amide derivatives and their application for the treatment of g protein related diseases |
PL2014652T3 (pl) | 2006-04-18 | 2015-02-27 | Nippon Chemiphar Co | Czynnik aktywujący receptor aktywowany przez proliferatory peroksysomów |
DE102006023336A1 (de) | 2006-05-18 | 2007-11-22 | Merck Patent Gmbh | 1,5-Diphenyl-pyrazole II |
CN101085772A (zh) * | 2006-06-07 | 2007-12-12 | 上海艾力斯医药科技有限公司 | 一类具有PPARγ激动剂活性的化合物及其应用 |
EP2128138A1 (en) | 2007-01-29 | 2009-12-02 | Takeda Pharmaceutical Company Limited | Pyrazole compound |
GB2460784A (en) | 2007-03-07 | 2009-12-16 | Dong A Pharmtech Co Ltd | Novel phenylpropionic acid derivatives as peroxisome proliferator-activated gamma receptor modulators,method of the same,and pharmaceutical composition |
JP2008285452A (ja) | 2007-05-21 | 2008-11-27 | Ono Pharmaceut Co Ltd | PPARα/γデュアルアゴニストおよび糖尿病治療薬を組み合わせてなる医薬 |
AU2008345009A1 (en) | 2007-12-28 | 2009-07-09 | The Salk Institute For Biological Studies | Methods for enhancing muscle performance and tone |
WO2014033088A1 (en) | 2012-08-28 | 2014-03-06 | Koc Universitesi | Bone plate |
JP2016520552A (ja) | 2013-04-05 | 2016-07-14 | ソーク インスティテュート フォー バイオロジカル スタディーズ | Pparアゴニスト |
ES2811087T3 (es) | 2013-09-09 | 2021-03-10 | Vtv Therapeutics Llc | Uso de agonistas de PPAR-delta para tratar la atrofia muscular |
WO2016057322A1 (en) | 2014-10-08 | 2016-04-14 | Salk Institute For Biological Studies | Ppar agonists and methods of use thereof |
US20170305894A1 (en) | 2014-10-08 | 2017-10-26 | Mitobridge, Inc. | Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof |
DK3359528T3 (en) | 2015-10-07 | 2022-03-07 | Mitobridge Inc | Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof |
KR102430906B1 (ko) | 2016-04-13 | 2022-08-10 | 미토브리지, 인크. | Ppar 효능제, 화합물, 제약 조성물, 및 그의 사용 방법 |
PL3523283T3 (pl) * | 2016-10-05 | 2021-12-13 | Mitobridge, Inc. | Postacie krystaliczne i postacie soli związków stanowiących agonistów ppar |
US20210283116A1 (en) | 2016-10-05 | 2021-09-16 | Mitobridge, Inc. | Methods of treating acute kidney injury |
-
2016
- 2016-10-05 DK DK16785611.1T patent/DK3359528T3/da active
- 2016-10-05 EP EP20193960.0A patent/EP3770146A1/en active Pending
- 2016-10-05 BR BR112018006866-7A patent/BR112018006866B1/pt active IP Right Grant
- 2016-10-05 CN CN202110286947.3A patent/CN113024467A/zh active Pending
- 2016-10-05 CO CONC2018/0004473A patent/CO2018004473A2/es unknown
- 2016-10-05 MA MA052648A patent/MA52648A/fr unknown
- 2016-10-05 ES ES16785611T patent/ES2906379T3/es active Active
- 2016-10-05 ES ES20193962T patent/ES2949852T3/es active Active
- 2016-10-05 MA MA052098A patent/MA52098A/fr unknown
- 2016-10-05 KR KR1020217032197A patent/KR20210126150A/ko active IP Right Grant
- 2016-10-05 PT PT167856111T patent/PT3359528T/pt unknown
- 2016-10-05 WO PCT/US2016/055521 patent/WO2017062468A1/en active Application Filing
- 2016-10-05 EA EA201890776A patent/EA037371B1/ru unknown
- 2016-10-05 CN CN202110284826.5A patent/CN113004205A/zh active Pending
- 2016-10-05 JP JP2018538052A patent/JP6657413B2/ja active Active
- 2016-10-05 MX MX2020011099A patent/MX2020011099A/es unknown
- 2016-10-05 HU HUE16785611A patent/HUE058154T2/hu unknown
- 2016-10-05 EP EP16785611.1A patent/EP3359528B1/en active Active
- 2016-10-05 AU AU2016333963A patent/AU2016333963C1/en active Active
- 2016-10-05 SG SG10201906400SA patent/SG10201906400SA/en unknown
- 2016-10-05 EP EP20193962.6A patent/EP3795566B1/en active Active
- 2016-10-05 MX MX2020011100A patent/MX2020011100A/es unknown
- 2016-10-05 KR KR1020187012860A patent/KR20180095797A/ko active IP Right Grant
- 2016-10-05 CA CA3000431A patent/CA3000431A1/en active Pending
- 2016-10-05 UA UAA201802841A patent/UA122237C2/uk unknown
- 2016-10-05 CN CN201680057879.0A patent/CN108349904B/zh active Active
- 2016-10-05 US US15/766,455 patent/US10399958B2/en active Active
- 2016-10-05 PL PL16785611T patent/PL3359528T3/pl unknown
- 2016-10-06 JO JOP/2016/0217A patent/JO3738B1/ar active
- 2016-10-07 TW TW108133069A patent/TWI730408B/zh active
- 2016-10-07 TW TW105132668A patent/TWI730006B/zh active
- 2016-10-07 TW TW108144723A patent/TWI742479B/zh active
-
2018
- 2018-03-19 IL IL258225A patent/IL258225B/en unknown
- 2018-03-27 ZA ZA2018/02029A patent/ZA201802029B/en unknown
- 2018-04-06 PH PH12018500762A patent/PH12018500762A1/en unknown
-
2019
- 2019-01-08 HK HK19100269.3A patent/HK1257907A1/zh unknown
- 2019-07-15 US US16/510,976 patent/US10479775B1/en active Active
- 2019-11-13 US US16/682,676 patent/US10906885B2/en active Active
- 2019-12-18 AU AU2019283837A patent/AU2019283837B2/en active Active
-
2020
- 2020-02-03 JP JP2020016147A patent/JP6866514B2/ja active Active
- 2020-06-15 IL IL275392A patent/IL275392B/en unknown
- 2020-06-15 IL IL275387A patent/IL275387B/en unknown
- 2020-06-18 ZA ZA2020/03662A patent/ZA202003662B/en unknown
- 2020-06-18 ZA ZA2020/03664A patent/ZA202003664B/en unknown
- 2020-06-18 ZA ZA2020/03663A patent/ZA202003663B/en unknown
- 2020-09-14 JO JOP/2020/0230A patent/JOP20200230A1/ar unknown
- 2020-09-14 JO JOP/2020/0231A patent/JOP20200231A1/ar unknown
- 2020-12-02 AU AU2020281069A patent/AU2020281069B2/en active Active
-
2021
- 2021-01-29 US US17/162,157 patent/US11578052B2/en active Active
-
2023
- 2023-02-13 US US18/108,785 patent/US20230373948A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA202003664B (en) | Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof | |
HK1243999A1 (zh) | 新型3-吲哚取代的衍生物、藥物組合物及使用方法 | |
IL247062A0 (en) | Heterocyclic compounds, their preparation and pharmaceutical preparations containing them | |
EP3139920A4 (en) | Anti-viral compounds, pharmaceutical compositions, and methods of use thereof | |
HUE056172T2 (hu) | Szelenoorganikus vegyületeket tartalmazó készítmények és eljárások alkalmazásukra | |
HK1259372A1 (zh) | 治療化合物、其組合物及使用方法 | |
EP3297640A4 (en) | Pharmaceutical co-crystal composition and use thereof | |
HK1243354B (zh) | 新穎碘伏組合物及其使用方法 | |
HK1256674A1 (zh) | 氘修飾的brigatinib衍生物、含有該化合物的藥物組合物及其用途 | |
IL280690A (en) | Pharmaceutical preparations that include DGLA and their use | |
EP3285758A4 (en) | Co-crystal composition and its pharmaceutical use | |
RO130539B8 (ro) | Compoziţie erbicidă, procedeu de preparare şi utilizarea acesteia | |
HK1258765A1 (zh) | 治療性化合物、組合物和它們的使用方法 | |
EP3151826A4 (en) | Omega-3 compositions, dosage forms, and methods of use | |
EP3175851A4 (en) | Use of butenylphthalide, usage method thereof and method for preparing same into pharmaceutical composition | |
HK1254738A1 (zh) | 用於進行最小量潤滑的組合物及其用途 | |
IL248578A0 (en) | Quinzoline derivatives, pharmaceutical compounds containing them and their uses | |
IL247645A0 (en) | Preparations of seleno-organic compounds and methods of using them | |
GB201408233D0 (en) | Use of polyanionic composition | |
GB201720445D0 (en) | Use of TRPV1 agonists | |
GB201620933D0 (en) | Use of TRPV1 agonists | |
PL3061765T3 (pl) | Pochodna protoescygeniny, sposób jej otrzymywania, zastosowanie i użycie w kompozycjach farmaceutycznych zawierających ten związek | |
GB201415969D0 (en) | Pharmaceutical compositions comprising of hetero-bicyclic derivatives, and methods of use thereof | |
TH149389B (th) | องค์ประกอบสารเคลือบใส กระบวนการสำหรับการเตรียมและการใช้ |